Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-label, Study to Evaluate the Safety and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV, MVA-BN-Filo in Adults and Children Originally Enrolled in the Control Arm of the EBOVAC-Salone Study
Conditions
Interventions
Ad26.ZEBOV, MVA-BN-Filo
Locations
1
Sierra Leone
EBOVAC Kambia 1 clinic
Kambia, Sierra Leone
Start Date
September 19, 2022
Primary Completion Date
March 2, 2023
Completion Date
October 31, 2024
Last Updated
May 11, 2025
NCT00018044
NCT06631287
NCT00344188
NCT07286370
NCT07297966
NCT06627764
Lead Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions